PRDS Key Statistics, Chart & Performance
The current stock price of PRDS is 2.16 USD. In the past month the price increased by 2.37%. In the past year, price decreased by -40%.
PRDS Latest News, Press Relases and Analysis
PRDS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.12 | 402.79B | ||
| AMGN | AMGEN INC | 15.67 | 184.56B | ||
| GILD | GILEAD SCIENCES INC | 15.2 | 154.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.64B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.28 | 77.02B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 914.63 | 61.62B | ||
| INSM | INSMED INC | N/A | 43.85B | ||
| NTRA | NATERA INC | N/A | 32.62B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 20.53B | ||
| INCY | INCYTE CORP | 15.88 | 20.01B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About PRDS
Company Profile
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The company went IPO on 2021-02-17. The firm is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.
Company Info
PARDES BIOSCIENCES INC
2173 Salk Avenue, Suite 250, Pmb#052
Carlsbad CALIFORNIA US
Employees: 57
Phone: 14156498758.0
PARDES BIOSCIENCES INC / PRDS FAQ
Can you describe the business of PARDES BIOSCIENCES INC?
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The company went IPO on 2021-02-17. The firm is focused on discovering, developing and commercializing novel therapeutics to treat and prevent viral diseases. Its lead product candidate, pomotrelvir, which targets the coronavirus disease (COVID-19). Pomotrelvir is in clinical development to treat COVID-19 in adult and pediatric patients. The Company, by leveraging its knowledge of structure-based drug design, reversible covalent chemistry and viral biology, it has discovered and is developing novel product candidates with low nanomolar potency against SARS-CoV-2 and activity against all known pathogenic human coronaviruses. Its lead product candidate, pomotrelvir, inhibits the main coronaviral cysteine protease (Mpro), a viral protein essential for replication of all known coronaviruses, including SARS-CoV-2. Inhibiting Mpro prevents the liberation and assembly of the viral replication complex, blocking replication before it begins.
Can you provide the latest stock price for PARDES BIOSCIENCES INC?
The current stock price of PRDS is 2.16 USD.
Does PARDES BIOSCIENCES INC pay dividends?
PRDS does not pay a dividend.
How is the ChartMill rating for PARDES BIOSCIENCES INC?
PRDS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting PRDS stock to perform?
6 analysts have analysed PRDS and the average price target is 1.27 USD. This implies a price decrease of -40.97% is expected in the next year compared to the current price of 2.16.
What is PARDES BIOSCIENCES INC worth?
PARDES BIOSCIENCES INC (PRDS) has a market capitalization of 133.95M USD. This makes PRDS a Micro Cap stock.
PRDS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PRDS. When comparing the yearly performance of all stocks, PRDS is a bad performer in the overall market: 72.9% of all stocks are doing better.
PRDS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PRDS. While PRDS has a great health rating, there are worries on its profitability.
PRDS Financial Highlights
Over the last trailing twelve months PRDS reported a non-GAAP Earnings per Share(EPS) of -1.29. The EPS increased by 12.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PRDS Forecast & Estimates
6 analysts have analysed PRDS and the average price target is 1.27 USD. This implies a price decrease of -40.97% is expected in the next year compared to the current price of 2.16.